Boniva (ibandronate sodium) Injection

Roche (Nutley, NJ) and Glaxo-SmithKline (Research Triangle Park, NC)recently received FDA approval forBoniva Injection—the first intravenous(IV) medication indicated for the treatmentof postmenopausal osteoporosis.The product is a member of the bisphosphonateclass, which is the most frequentlyprescribed medicine for osteoporosis.Boniva Injection, administered asa 15-to 30-second IV injection, will providean alternative for patients who havedifficulty with oral bisphosphonate dosingrequirements. Furthermore, becausethe product will be administered onceevery 3 months by health care professionals,clinicians will have a greaterawareness of patient compliance withtherapy. Boniva Injection 3 mg/3 mL willbe available in boxes containing one single-use, clear glass prefilled syringe,along with 1 needle and an alcohol swab.For more information, visit www.gsk.comor www.rocheusa.com.